FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/10/2015 |
3. Issuer Name and Ticker or Trading Symbol
KERYX BIOPHARMACEUTICALS INC [ KERX ] |
|||||||||||||
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock (Restricted) | 40,000(1) | D | |
Common Stock (Restricted) | 23,875(2) | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Options (Right to Buy) | 04/14/2015(3) | 04/14/2024 | Common Stock | 60,000 | $14.06 | D | |
Stock Options (Right to Buy) | 01/04/2016(4) | 01/04/2025 | Common Stock | 47,750 | $14.34 | D |
Explanation of Responses: |
1. The 40,000 shares are restricted common stock, with one-third of the 40,000 shares vesting on April 14, 2015, and one-twelfth vesting on each of July 14, 2015, October 14, 2015, January 14, 2016, April 14, 2016, July 14, 2016, October 14, 2016, January 14, 2017and April 14, 2017. |
2. The 23,875 shares are restricted common stock, with one-third of the 23,875 shares vesting on January 4, 2016, and one-twelfth vesting on each of April 4, 2016, July 4, 2016, October 4, 2016, January 4, 2017, April 4, 2017, July 4, 2017, October 4, 2017, and January 4, 2018. |
3. The options vest according to the following schedule: one-third of the 60,000 options vesting on April 14, 2015, and one-twelfth vesting on each of July 14, 2015, October 14, 2015, January 14, 2016, April 14, 2016, July 14, 2016, October 14, 2016, January 14, 2017and April 14, 2017. |
4. The options vest according to the following schedule: one-third of the 47,750 options will vest on January 4, 2016, and one-twelfth will vest on each of April 4, 2016, July 4, 2016, October 4, 2016, January 4, 2017, April 4, 2017, July 4, 2017, October 4, 2017, and January 4, 2018. |
Remarks: |
/s/ James F. Oliviero, Attorney-in-Fact | 03/16/2015 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |